GRAIL (NASDAQ:GRAL) Now Covered by Analysts at Mizuho

Mizuho began coverage on shares of GRAIL (NASDAQ:GRAL) in a research report released on Friday, Marketbeat Ratings reports. The brokerage issued a neutral rating and a $58.00 target price on the stock.

GRAL has been the topic of a number of other research reports. Morgan Stanley dropped their price objective on GRAIL from $110.00 to $60.00 and set an “equal weight” rating on the stock in a report on Tuesday, February 24th. Weiss Ratings reissued a “sell (d-)” rating on shares of GRAIL in a report on Thursday, January 22nd. Robert W. Baird set a $82.00 target price on GRAIL in a report on Friday, February 20th. TD Cowen raised GRAIL from a “hold” rating to a “buy” rating and set a $65.00 target price on the stock in a report on Wednesday, March 18th. Finally, Canaccord Genuity Group lowered their target price on GRAIL from $105.00 to $80.00 and set a “buy” rating on the stock in a report on Friday, February 20th. Four investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, GRAIL currently has an average rating of “Hold” and an average target price of $68.63.

GRAIL Price Performance

Shares of GRAL stock opened at $45.63 on Friday. The business’s fifty day moving average price is $63.91 and its 200 day moving average price is $79.53. GRAIL has a 1-year low of $22.30 and a 1-year high of $118.84. The firm has a market capitalization of $1.87 billion, a PE ratio of -4.08 and a beta of 4.62.

GRAIL (NASDAQ:GRAL) last announced its quarterly earnings data on Thursday, February 19th. The company reported ($2.44) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.33) by $0.89. GRAIL had a negative return on equity of 17.11% and a negative net margin of 277.46%.The firm had revenue of $43.60 million for the quarter, compared to analyst estimates of $43.33 million. Equities research analysts expect that GRAIL will post -15.15 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Robert P. Ragusa sold 123,502 shares of the stock in a transaction on Wednesday, April 8th. The stock was sold at an average price of $49.92, for a total transaction of $6,165,219.84. Following the sale, the chief executive officer owned 518,582 shares of the company’s stock, valued at $25,887,613.44. This trade represents a 19.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, President Joshua J. Ofman sold 61,665 shares of the stock in a transaction on Wednesday, April 8th. The shares were sold at an average price of $49.92, for a total value of $3,078,316.80. Following the sale, the president directly owned 371,216 shares in the company, valued at approximately $18,531,102.72. The trade was a 14.25% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 310,267 shares of company stock worth $15,485,396 in the last ninety days. Insiders own 1.85% of the company’s stock.

Institutional Trading of GRAIL

A number of large investors have recently made changes to their positions in GRAL. Farallon Capital Management LLC boosted its stake in shares of GRAIL by 73.7% during the fourth quarter. Farallon Capital Management LLC now owns 2,342,684 shares of the company’s stock valued at $200,510,000 after acquiring an additional 993,684 shares during the last quarter. Morgan Stanley boosted its stake in shares of GRAIL by 63.8% during the fourth quarter. Morgan Stanley now owns 1,511,687 shares of the company’s stock valued at $129,385,000 after acquiring an additional 588,647 shares during the last quarter. State Street Corp boosted its stake in shares of GRAIL by 38.8% during the fourth quarter. State Street Corp now owns 1,827,523 shares of the company’s stock valued at $156,418,000 after acquiring an additional 510,546 shares during the last quarter. Baker BROS. Advisors LP boosted its stake in shares of GRAIL by 27.9% during the fourth quarter. Baker BROS. Advisors LP now owns 2,085,333 shares of the company’s stock valued at $178,484,000 after acquiring an additional 455,208 shares during the last quarter. Finally, Alyeska Investment Group L.P. acquired a new stake in shares of GRAIL during the fourth quarter valued at $37,874,000.

GRAIL News Summary

Here are the key news stories impacting GRAIL this week:

• Positive Sentiment: Analyst consensus remains constructive: Street coverage still shows an average rating of “Moderate Buy” with a consensus price target around $72.83, implying meaningful upside from current levels. Article Title
• Neutral Sentiment: Mizuho initiated coverage with a “neutral” rating and a $58 price target (roughly mid‑teens to low‑20s % upside vs. current quoted levels); the call is cautious and reflects uncertainty rather than outright bullishness. Article Title
• Neutral Sentiment: Piper Sandler also initiated coverage with a “neutral” rating and a $54 price target, signaling analyst caution and limited near‑term conviction. Article Title
• Negative Sentiment: Reported study setback: coverage initiation notes reference a recent study disappointment that prompted the neutral stances — clinical execution and near‑term data risk are now front and center for investors. Article Title
• Negative Sentiment: Insider selling by senior management: CEO, President and CFO sold sizable blocks on April 8 (CEO ~123,502 shares; President ~61,665; CFO ~45,806), materially reducing their holdings — a strong negative signal to the market and a likely contributor to downward pressure. Article Title

GRAIL Company Profile

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.